PMID- 31966383
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200126
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 10
IP  - 10
DP  - 2017
TI  - Concordance of immunohistochemistry and fluorescence in situ hybridization for 
      assessment of HER2 status in breast cancer patients in Xinjiang autonomous 
      region, China.
PG  - 10459-10466
AB  - OBJECTIVE: To investigate the concordance rate between Immunohistochemistry (IHC) 
      and fluorescence in situ hybridization (FISH) for assessment of HER2 status in 
      breast cancer in Uighur ethnic minority and Han population in Xinjiang province, 
      China. METHODS: Between January 2010 and June 2016, paraffin-embedded specimens 
      form 1032 cases of breast cancer at the Tumor Hospital Affiliated to the Xinjiang 
      Medical University were examined for HER2 status via both IHC and FISH using 
      standard methodologies. The concordance between the two methods was then 
      statistically evaluated. RESULTS: The IHC 0, 1+ and 3+ cases had a high 
      concordance rate of 100%, 90.6% and 91.7%, respectively. The IHC 2+ had a low 
      concordance rate (64.4%). 78.6% (293/373) HER2 positive specimens (2+ and 3+) 
      showed HER2 gene amplification and 95.1% (627/659) HER negative cases (0 and 1+) 
      were HER2 non-amplified, yielding a kappa score of 0.7581 (P < 0.0001). IHC 
      negative 0 and FISH had a high concordance rate of 100% in both populations. Han 
      and Uighur population had similar concordance rate between IHC (0, 1+ and 3+) and 
      FISH (100% vs. 100%, 89.0% vs. 94.7% and 91.0% vs. 94.6%). Both populations had 
      low concordance rate (63.1% vs. 71.0%) for IHC 2+ cases. HER2 status showed 
      significant correlation with tumor size (P = 0.000). The Uighur minority had a 
      lower HER2 amplification rate compared with Han population. CONCLUSION: IHC can 
      be used as an initial screening test of HER2 status for both populations in 
      Xinjiang province. However, for cases with a HER2 IHC 2+ result, a FISH test is 
      required for confirmation.
CI  - IJCEP Copyright (c) 2017.
FAU - Zhao, Bing
AU  - Zhao B
AD  - Oncology Day Unit, Tumor Hospital of Xinjiang Medical University Urumqi, 
      Xinjiang, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Cadres Health Care, People's Hospital of Xinjiang Vygur Autonomous 
      Region Urumqi, China.
FAU - Xu, Hang
AU  - Xu H
AD  - Intensive Care Unit, The Sixth Affiliated Hospital, Xinjiang Medical University 
      Urumqi, Xinjiang, China.
LA  - eng
PT  - Journal Article
DEP - 20171001
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC6965800
OTO - NOTNLM
OT  - Breast cancer
OT  - HER2 gene
OT  - anti-HER2 therapy
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry
COIS- None.
EDAT- 2017/10/01 00:00
MHDA- 2017/10/01 00:01
PMCR- 2017/10/01
CRDT- 2020/01/23 06:00
PHST- 2017/06/11 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2020/01/23 06:00 [entrez]
PHST- 2017/10/01 00:00 [pubmed]
PHST- 2017/10/01 00:01 [medline]
PHST- 2017/10/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2017 Oct 1;10(10):10459-10466. eCollection 2017.